Showing 2591-2600 of 5909 results for "".
- ASCRS: Insurance Company Policy Delays Sight-Restoring Surgery, Puts Patients in Jeopardyhttps://modernod.com/news/ascrs-insurance-company-policy-delays-sight-restoring-surgery-puts-patients-in-jeopardy/2479334/The decision by Aetna to require preauthorization of all cataract surgery procedures went into effect July 1. In a news release, ASCRS said it is opposed to the preauthorization policy, stating it will create delays i
- PYC Therapeutics Announces Preclinical Results Demonstrating VP-002 Program’s Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophyhttps://modernod.com/news/pyc-therapeutics-announces-comprehensive-preclinical-results-demonstrating-vp-002-programs-potential-as-the-first-disease-modifying-therapy-for-autosomal-dominant-optic-atrophy/2479330/PYC Therapeutics released a summary of preclinical findings supporting the potential of PYC’s VP-002 program as the first disease-modifying therapy for patients suffering from Autosomal Dominant Optic Atrophy (ADOA). PYC’s PPMO technology used in the VP-002 program significantly increases levels
- FDA Accepts Application for Genentech’s Port Delivery System with Ranibizumab (PDS) for Treatment of Wet AMDhttps://modernod.com/news/fda-accepts-application-for-genentechs-port-delivery-system-with-ranibizumab-pds-for-treatment-of-wet-amd/2479322/Genentech announced that the FDA has accepted the company’s Biologics License Application (BLA), under Priority Review, for Port Delivery System with ranibizumab (PDS) for the treatment of wet age-related macular degeneration (AMD). If approved, PDS would be a first-of-its-kind therapeutic approa
- Bausch + Lomb Expands Parameters for Bausch + Lomb Ultra Multifocal for Astigmatism Contact Lenseshttps://modernod.com/news/bausch-lomb-expands-parameters-for-bausch-lomb-ultra-multifocal-for-astigmatism-contact-lenses/2479319/Bausch + Lomb announced the US launch of expanded parameters for Bausch + Lomb ULTRA Multifocal for Astigmatism contact lenses. The expansion, which includes the addition of -2.25D and -2.75D cylinder power parameters, will be part of the company’s standard offering of the lens and will ext
- Gyroscope Announces Research Collaboration with CMRI to Develop Gene Therapy Capsidshttps://modernod.com/news/gyroscope-announces-research-collaboration-with-cmri-to-develop-gene-therapy-capsids/2479315/Gyroscope Therapeutics announced the company has entered a research collaboration with Children’s Medical Research Institute (CMRI) in Australia to develop next-generation clinical capsids, the protein shells of viral vectors used to deliver gene therapies. A team of researchers from CMRI
- CooperVision Announces Uniform Markings Across Blanchard Onefit Family of Scleral Lenseshttps://modernod.com/news/coopervision-announces-uniform-markings-across-blanchard-onefit-family-of-scleral-lenses/2479312/CooperVision Specialty EyeCare announced that lens markings are now uniform across the entire Blanchard Onefit family of scleral lenses, including Onefit MED and Onefit MED+. The uniform markings for front torics and toric haptics across the Onefit family aid in distinguishing whether quadrant sp
- Tarsus Announces Positive Results of Saturn-1 Trial Evaluating TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-announces-positive-results-of-saturn-1-trial-evaluating-tp-03-for-the-treatment-of-demodex-blepharitis/2479309/Tarsus Pharmaceuticals announced that all pre-specified primary and secondary endpoints were met for its pivotal Phase 2b/3 Saturn-1 trial evaluating the company’s novel investigational therapeutic, TP-03 (lotilaner ophthalmic solution, 0.25%), in patients with Demodex blepharitis. Results demons
- Noveome Biotherapeutics Announces Preliminary Results of its Phase 1 Trial Evaluating Intranasal Delivery of ST266 In Glaucoma Suspect Patientshttps://modernod.com/news/noveome-biotherapeutics-announces-preliminary-results-of-its-phase-1-trial-evaluating-intranasal-delivery-of-st266-in-glaucoma-suspect-patients/2479275/Noveome Biotherapeutics announced preliminary results of a phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in glaucoma suspect patients. The trial was conducted at the University of Pennsylvania by Ahmara Ross, MD, PhD, and Kenneth Shindler, MD, PhD,
- Bausch + Lomb and Lochan Enter Into Agreement to Develop the Next-Generation of Eyetelligence Clinical Decision Support Softwarehttps://modernod.com/news/bausch-lomb-and-lochan-enter-into-agreement-to-develop-the-next-generation-of-eyetelligence-clinical-decision-support-software/2479271/Bausch + Lomb announced that its affiliate has entered into an agreement with Lochan LLC to develop the next-generation of Bausch + Lomb’s eyeTELLIGENCE clinical decision support software. Using the existing cloud-based infrastructure of eyeTELLIGENCE, this analytical software is being designed t
- Notal Vision Raises Up to $60 Million to Support Development of its Home OCT Technologyhttps://modernod.com/news/notal-vision-raises-up-to-60-million-to-support-development-of-its-home-oct-technology/2479251/Notal Vision announced the closing of a Series D financing to support the commercial growth of the company’s current service, the ForeseeHome AMD Monitoring Program, as well as the go-to-market strategy for its Home OCT pipeline technology. The financing was co-led by Soleus Capital and the compa